Extended Data Fig. 2: In vitro reactive astrocytes correspond to in vivo counterparts.
From: A phenotypic screening platform for identifying chemical modulators of astrocyte reactivity
a, Enrichment map of gene ontology terms for genes upregulated in reactive vs physiological astrocytes. b, Enrichment map of gene ontology terms for genes upregulated in physiological vs reactive astrocytes. c, Representative images of physiological astrocytes, astrocytes exposed to TIC cytokines and astrocytes infected with TMEV and stained for double stranded RNA to show viral infection (dsRNA in green) and GBP2 (red). d, Quantification of the percentage of astrocytes that are positive for the viral marker dsRNA. Data presented as mean ± s.e.m for n = 3 biological replicates, with p-value calculated by a one-way ANOVA. e, Quantification of the percentage of astrocytes that are GBP2 positive. Data presented as mean ± s.e.m for n = 3 biological replicates, with p-value calculated by a one-way ANOVA with Dunnett correction for multiple comparisons. f, Quantitative PCR results comparing the expression of pathological reactive astrocyte markers Gbp2 and Psmb8 by physiological astrocytes, astrocytes exposed to TIC cytokines and astrocytes infected with TMEV. P-value calculated by one-way ANOVA with Dunnett correction for multiple comparisons. g, UMAP plots from integrated single-cell RNA-seq analysis of in vitro physiological and reactive astrocytes from this study with in vivo astrocytes from LPS or vehicle treated mice46. h, Frequency of cells distributed across different astrocyte clusters. i, Expression of pathological reactive astrocyte genes and astrocyte marker genes in each single-cell cluster. j, Gene ontology results showing enriched terms for genes enriched in clusters 2, 6 and 7 that contain mainly astrocytes from reactive cultures and LPS treated mice. P-values generated by Benjamini-Hochberg false discovery rate.
